Cargando…

Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy

Hepatocellular carcinoma (HCC) remains a serious medical therapeutic challenge as conventional curative avenues such as surgery and chemotherapy only benefit for few patients with limited tumor burden. Immunotherapy achieves clinical progress in the treatment of this prevalent malignant disease by v...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Hai, Zhuo, Yunhui, Zhang, Xuemei, Li, Yuyao, Li, Yue, Duan, Xiangjuan, Shi, Jia, Xu, Chengbin, Gao, Yueqiu, Yu, Zhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618253/
https://www.ncbi.nlm.nih.gov/pubmed/36320666
http://dx.doi.org/10.2147/JHC.S381764
_version_ 1784821009750163456
author Feng, Hai
Zhuo, Yunhui
Zhang, Xuemei
Li, Yuyao
Li, Yue
Duan, Xiangjuan
Shi, Jia
Xu, Chengbin
Gao, Yueqiu
Yu, Zhuo
author_facet Feng, Hai
Zhuo, Yunhui
Zhang, Xuemei
Li, Yuyao
Li, Yue
Duan, Xiangjuan
Shi, Jia
Xu, Chengbin
Gao, Yueqiu
Yu, Zhuo
author_sort Feng, Hai
collection PubMed
description Hepatocellular carcinoma (HCC) remains a serious medical therapeutic challenge as conventional curative avenues such as surgery and chemotherapy only benefit for few patients with limited tumor burden. Immunotherapy achieves clinical progress in the treatment of this prevalent malignant disease by virtue of the development of tumor immunology; however, most patients have experienced minimal or no clinical benefit in terms of overall survival. The complexity and diversity of tumor microenvironment (TME) built by immune and stromal cell subsets has been considered to be responsible for the insufficiency of immunotherapy. The advance of bioanalytical technology boosts the exploration of the composition and differentiation of these infiltrated cells, which reflect the immune state of the TME and impact the efficacy of the antitumor immune response. Targeting these cells to remodel the TME is one of the important immunotherapeutic approaches to improve HCC treatment. In this review, we focused on the role of these non-cancerous cells in the tumor progression, and elaborated their function on cancer immunotherapy when manipulating them as potential targets.
format Online
Article
Text
id pubmed-9618253
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-96182532022-10-31 Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy Feng, Hai Zhuo, Yunhui Zhang, Xuemei Li, Yuyao Li, Yue Duan, Xiangjuan Shi, Jia Xu, Chengbin Gao, Yueqiu Yu, Zhuo J Hepatocell Carcinoma Review Hepatocellular carcinoma (HCC) remains a serious medical therapeutic challenge as conventional curative avenues such as surgery and chemotherapy only benefit for few patients with limited tumor burden. Immunotherapy achieves clinical progress in the treatment of this prevalent malignant disease by virtue of the development of tumor immunology; however, most patients have experienced minimal or no clinical benefit in terms of overall survival. The complexity and diversity of tumor microenvironment (TME) built by immune and stromal cell subsets has been considered to be responsible for the insufficiency of immunotherapy. The advance of bioanalytical technology boosts the exploration of the composition and differentiation of these infiltrated cells, which reflect the immune state of the TME and impact the efficacy of the antitumor immune response. Targeting these cells to remodel the TME is one of the important immunotherapeutic approaches to improve HCC treatment. In this review, we focused on the role of these non-cancerous cells in the tumor progression, and elaborated their function on cancer immunotherapy when manipulating them as potential targets. Dove 2022-10-26 /pmc/articles/PMC9618253/ /pubmed/36320666 http://dx.doi.org/10.2147/JHC.S381764 Text en © 2022 Feng et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Feng, Hai
Zhuo, Yunhui
Zhang, Xuemei
Li, Yuyao
Li, Yue
Duan, Xiangjuan
Shi, Jia
Xu, Chengbin
Gao, Yueqiu
Yu, Zhuo
Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy
title Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy
title_full Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy
title_fullStr Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy
title_full_unstemmed Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy
title_short Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy
title_sort tumor microenvironment in hepatocellular carcinoma: key players for immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618253/
https://www.ncbi.nlm.nih.gov/pubmed/36320666
http://dx.doi.org/10.2147/JHC.S381764
work_keys_str_mv AT fenghai tumormicroenvironmentinhepatocellularcarcinomakeyplayersforimmunotherapy
AT zhuoyunhui tumormicroenvironmentinhepatocellularcarcinomakeyplayersforimmunotherapy
AT zhangxuemei tumormicroenvironmentinhepatocellularcarcinomakeyplayersforimmunotherapy
AT liyuyao tumormicroenvironmentinhepatocellularcarcinomakeyplayersforimmunotherapy
AT liyue tumormicroenvironmentinhepatocellularcarcinomakeyplayersforimmunotherapy
AT duanxiangjuan tumormicroenvironmentinhepatocellularcarcinomakeyplayersforimmunotherapy
AT shijia tumormicroenvironmentinhepatocellularcarcinomakeyplayersforimmunotherapy
AT xuchengbin tumormicroenvironmentinhepatocellularcarcinomakeyplayersforimmunotherapy
AT gaoyueqiu tumormicroenvironmentinhepatocellularcarcinomakeyplayersforimmunotherapy
AT yuzhuo tumormicroenvironmentinhepatocellularcarcinomakeyplayersforimmunotherapy